The short answer
A bleeding interaction between turmeric and dalteparin has not been demonstrated. A small human study found no overall clinically important clotting effect from its turmeric product, including with aspirin, but it did not test dalteparin.
What this answer covers
Oral Curcuma longa product with subcutaneous dalteparin sodium; whole-herb products, isolated curcumin and enhanced-absorption formulations are not interchangeable.
- Supplement or preparation
- Curcuma longa
- Medication ingredient
- dalteparin
What the human trial found
The randomized study tested turmeric alone and with aspirin. Overall platelet and clotting measurements did not show clinically important impairment, and no significant bleeding manifestations were reported. Five of 24 evaluable turmeric participants showed inhibition with one platelet stimulus.
What this leaves uncertain
A small, short study cannot exclude uncommon bleeding. Aspirin is a platelet inhibitor, while dalteparin is an injectable low-molecular-weight heparin. Results with aspirin cannot establish either safety or added bleeding with dalteparin.
The preparation matters
The inspected abstract does not fully characterize the turmeric preparation. It should not be treated as evidence for every curcumin dose or product containing absorption enhancers. Bring the actual ingredients and amount to the treatment team.
No established spacing rule
No reviewed evidence establishes universal avoidance or a protective interval between turmeric and dalteparin. Discuss supplements with the treatment team and report unusual bleeding promptly. Do not alter prescribed dalteparin yourself.
Evidence and practical considerations
Side effects & toxicity
No direct dalteparin clinical bleeding evidence; indirect original human findings include null results and cannot establish this broad increased-risk claim.
- Exact scope
- Oral Curcuma longa product with subcutaneous dalteparin sodium; whole-herb products, isolated curcumin and enhanced-absorption formulations are not interchangeable. with Subcutaneous dalteparin sodium; active ingredient bridge to RxCUI67109 IN. Not UFH or another LMWH.
- Medication form and route
- subcutaneous dalteparin; oral supplement
What remains uncertain
- Source-specific population, preparation and endpoint limits apply; no universal dose or timing rule.
Factors that may matter: Exact preparation; Dose and duration; Kidney function; Other medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients receiving subcutaneous dalteparin sodium.
Bleeding risk can increase with platelet inhibitors and other anticoagulants. Hyperkalemia is listed among postmarketing reports, whose frequency and causal relationship cannot reliably be established.
How this applies: Exact dalteparin sodium injection product and route; no silent transfer of unfractionated-heparin dosing or monitoring rules.
Does not specifically name these supplements. Not unfractionated heparin, another LMWH, an oral anticoagulant or topical therapy.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy volunteers; 25 recruited for the turmeric group, 24 evaluable.
No clinically relevant overall effect on platelet/coagulation function, no added aspirin platelet inhibition, and no significant bleeding manifestations. A few participants had inhibition on one platelet stimulus.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as dalteparin.
25 volunteers recruited per herb; product standardization incompletely described in abstract. Aspirin is not dalteparin. Small short study cannot exclude rare bleeding.
Research assessment: · Open full citations ↗
Timing & monitoring
No universal avoidance or protective spacing interval established; individual product and bleeding-risk review is appropriate.
- Exact scope
- Oral Curcuma longa product with subcutaneous dalteparin sodium; whole-herb products, isolated curcumin and enhanced-absorption formulations are not interchangeable. with Subcutaneous dalteparin sodium; active ingredient bridge to RxCUI67109 IN. Not UFH or another LMWH.
- Medication form and route
- subcutaneous dalteparin; oral supplement
What remains uncertain
- Source-specific population, preparation and endpoint limits apply; no universal dose or timing rule.
Factors that may matter: Exact preparation; Dose and duration; Kidney function; Other medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients receiving subcutaneous dalteparin sodium.
Bleeding risk can increase with platelet inhibitors and other anticoagulants. Hyperkalemia is listed among postmarketing reports, whose frequency and causal relationship cannot reliably be established.
How this applies: Exact dalteparin sodium injection product and route; no silent transfer of unfractionated-heparin dosing or monitoring rules.
Does not specifically name these supplements. Not unfractionated heparin, another LMWH, an oral anticoagulant or topical therapy.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy volunteers; 25 recruited for the turmeric group, 24 evaluable.
No clinically relevant overall effect on platelet/coagulation function, no added aspirin platelet inhibition, and no significant bleeding manifestations. A few participants had inhibition on one platelet stimulus.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as dalteparin.
25 volunteers recruited per herb; product standardization incompletely described in abstract. Aspirin is not dalteparin. Small short study cannot exclude rare bleeding.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact dalteparin article with independently checked product label and explicit limits on indirect supplement evidence. | |
| Research summary published |
Article revision: 098f2fc668e71c04
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.